Study procedure
BLOOD
Participants first came for a screening visit, which included medical history, standard physical examination and BP measurement. Blood was sampled for determination of HbAAfter inclusion, participants were randomly assigned to treatment with magnesium gluconate or matching placebo for 6 weeks in a crossover design (electronic supplementary material [ESM] Fig. At the end of each treatment period of 6 weeks, participants underwent a hyperinsulinaemic–euglycaemic clamp (target glucose 5.5 mmol/l) [